On May 15, 2015 the FDA announced it is investigating an association between Farxiga, Jardiance, and Invokana with diabetic ketoacidosis (DKA), ketoacidosis, or ketosis.  See: “FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood”. About a month later, Health Canada […]Read More